Overall rank by patents
#38,783
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 1 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
Adaptivendo holds 6 US patents across 1 technology areas, rank #38,783 of 50,000 tracked assignees.
Adaptivendo Llc has been granted 6 US utility patents between 2023 and 2025, placing Adaptivendo Llc at rank #38,783 across all assignees tracked by PlainPatent. This portfolio spans 1 distinct Cooperative Patent Classification (CPC) subclasses, averaging 3.0 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Adaptivendo Llc is one of the more focused assignees in the PatentsView dataset. By volume, Adaptivendo sits between Acumen Pharmaceuticals, Inc. (6 patents, rank #38,779) and Admiemobile Llc (6 patents, rank #38,787) - the closest US assignees by grant volume. The composite Innovation Score of 32.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Adaptivendo Llc's 3.0 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 1 subclass reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Adaptivendo Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Acumen Pharmaceuticals, Inc.
6 patents
AdSupply, Inc.
6 patents
Adamas Pharmaceuticals, Inc.
6 patents
Adant Technologies, Inc.
6 patents
Adaptive Capacity Labs, LLC
6 patents
Adaptive Regelsysteme Gesellschaft m.b.H.
6 patents
AdlOptica Optical Systems GmbH
6 patents
AdmieMobile LLC
6 patents
AdaptivEndo LLC
6 patents
What this shows Adaptivendo holds 6 patents at rank #38,783, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #38,783 in granted patent volume.
Other assignees with the most granted patents in Adaptivendo's primary technology class.
Adaptivendo's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 60% higher than 40% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 1 | 16.7% |
| 2024 | 3 | 50.0% |
| 2025 | 2 | 33.3% |
Top 1 of 1 technology areas
Overall rank by patents
#38,783
Across all tracked assignees
32.1 out of 100
How to use this portfolio
Adaptivendo's 6 grants land it in the top 60% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.